British Journal of Clinical Pharmacology

Papers
(The H4-Index of British Journal of Clinical Pharmacology is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
The Medication Adherence Report Scale: A measurement tool for eliciting patients' reports of nonadherence176
Recent developments of HDAC inhibitors: Emerging indications and novel molecules159
Potentially inappropriate prescribing and its associations with health‐related and system‐related outcomes in hospitalised older adults: A systematic review and meta‐analysis58
Underrepresentation of the elderly in clinical trials, time for action56
Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta‐analysis56
Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls48
Mass balance, pharmacokinetics and pharmacodynamics of intravenous HSK3486, a novel anaesthetic, administered to healthy subjects48
Machine learning in pharmacometrics: Opportunities and challenges48
Warfarin and food, herbal or dietary supplement interactions: A systematic review47
Warfarin dosing algorithms: A systematic review39
Potential role of IL‐17 blocking agents in the treatment of severe COVID‐19?39
Acute liver injury following turmeric use in Tuscany: An analysis of the Italian Phytovigilance database and systematic review of case reports38
Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre‐COVID‐19 reports38
Pharmacovigilance‐based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections37
Strategies to reduce use of antidepressants36
Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID‐1936
Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database36
Zinc supplementation as an adjunct therapy for COVID‐19: Challenges and opportunities35
Drug–drug interactions with warfarin: A systematic review and meta‐analysis35
Identification of different side effects between PARP inhibitors and their polypharmacological multi‐target rationale35
Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO35
Me‐too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists34
TDM is dead. Long live TCI!34
Trends in polypharmacy and potentially inappropriate medication (PIM) in older and middle‐aged people treated for diabetes34
Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis34
Effects of the dual sodium–glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure32
Changes in antibiotic prescribing following COVID‐19 restrictions: Lessons for post‐pandemic antibiotic stewardship32
Effect of lipophilicity on drug distribution and elimination: Influence of obesity31
The effects of acute and sustained cannabidiol dosing for seven days on the haemodynamics in healthy men: A randomised controlled trial31
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours31
Advances and roadblocks in the treatment of malaria30
A placebo‐controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans30
0.040068864822388